Alpha-1 antitrypsin (AAT) is the canonical serine protease inhibitor of neutrophil-derived proteases and can modulate innate immune mechanisms through its anti-inflammatory activities mediated by a broad spectrum of protein, cytokine, and cell surface interactions. AAT contains a reactive methionine residue that is critical for its protease-specific binding capacity, whereby AAT entraps the protease on cleavage of its reactive centre loop, neutralises its activity by key changes in its tertiary structure, and permits removal of the AAT-protease complex from the circulation. Recently, however, the immunomodulatory role of AAT has come increasingly to the fore with several prominent studies focused on lipid or protein-protein interactions that are predominantly mediated through electrostatic, glycan, or hydrophobic potential binding sites. The aim of this review was to investigate the spectrum of AAT molecular interactions, with newer studies supporting a potential therapeutic paradigm for AAT augmentation therapy in disorders in which a chronic immune response is strongly linked.
The present study describes the structural characterization and biotechnological application of a dirhamnolipid biosurfactant produced by Pseudomonas aeruginosa strain NBTU-01 isolated from a petroleum oil-contaminated soil sample. Characterization of partially purified biosurfactant by LC-MS/MS analysis indicated predominant production (78%) of dirhamnolipids Rha-Rha-C10-C10 and Rha-Rha-C12-C10 with a minor production of monorhamnolipids (22%). NMR analysis of the purified major biosurfactant produced by P. aeruginosa strain NBTU-01 identified it as dirhamnolipid and its deduced structure was L-rhamnosyl-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate. The LC-MS/MS analysis of intracellular proteins of P. aeruginosa strain NBTU-01 identified key enzymes and other proteins associated with regulation and biosynthesis of rhamnolipids. Critical micelle concentration of purified dirhamnolipid biosurfactant was determined at 72 ± 2.25 mg l−1 and it reduced the surface tension of water from 72.2 to 29.5 mN m−1. The crude rhamnolipid biosurfactant effectively emulsified crude petroleum-oil, diesel, kerosene and coconut oil, and removed 70 ± 3.5% crude petroleum oil from a saturated sand pack column. Heating the crude rhamnolipid biosurfactant at 100 °C for 5 h did not affect oil recovery from the sand pack column. Moreover, rhamnolipid biosurfactant showed stability at pH values between 6.0 and 10.0. The crystallization and melting temperature of purified dirhamnolipid biosurfactant was found to be 99 and 134 °C, respectively, suggesting it can withstand thermal denaturation and is suitable for application in high temperature wells for tertiary oil recovery.
The harnessing of medicinal plants containing a plethora of bioactive molecules may lead to the discovery of novel, potent and safe therapeutic agents to treat thrombosis-associated cardiovascular diseases. A 35 kDa (m/z 34747.5230) serine protease (lunathrombase) showing fibrin(ogen)olytic activity and devoid of N- and O- linked oligosaccharides was purified from an extract of aqueous leaves from L. indica. The LC-MS/MS analysis, de novo sequencing, secondary structure, and amino acid composition determination suggested the enzyme’s novel characteristic. Lunathrombase is an αβ-fibrinogenase, demonstrating anticoagulant activity with its dual inhibition of thrombin and FXa by a non-enzymatic mechanism. Spectrofluorometric and isothermal calorimetric analyses revealed the binding of lunathrombase to fibrinogen, thrombin, and/or FXa with the generation of endothermic heat. It inhibited collagen/ADP/arachidonic acid-induced mammalian platelet aggregation, and demonstrated antiplatelet activity via COX-1 inhibition and the upregulation of the cAMP level. Lunathrombase showed in vitro thrombolytic activity and was not inhibited by endogenous protease inhibitors α2 macroglobulin and antiplasmin. Lunathrombase was non-cytotoxic to mammalian cells, non-hemolytic, and demonstrated dose-dependent (0.125–0.5 mg/kg) in vivo anticoagulant and plasma defibrinogenation activities in a rodent model. Lunathrombase (10 mg/kg) did not show toxicity or adverse pharmacological effects in treated animals.